抗生物質耐性の世界市場レポート 2025

抗生物質耐性市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は7.1％で、169億7,000万米ドルに成長します。予測期間の成長は、不完全な治療コース、世界化と旅行、不十分な感染予防と管理、セルフメディケーション、異種トランスミッション、高い人口密度に起因すると考えられます。予測期間の主な動向には、ドラッグデリバリーにおける技術革新、サーベイランスのための世界な連携、人工知能の役割拡大、新規療法の急増などが含まれます。

薬剤耐性感染症の増加は、今後の抗生物質耐性市場の成長を促進すると予想されます。薬剤耐性感染症は、耐性を獲得した細菌によって引き起こされ、感染症の治療が著しく困難になる、あるいは不可能になることさえあります。抗菌薬耐性治療薬は、耐性メカニズムやマイクロバイオームコミュニティの相互作用の特異性に応じて、標的病原体と非標的病原体の両方に対する抗生物質治療の成果を改善することで、さまざまな薬剤耐性感染症の治療を支援します。例えば、2023年11月、政府機関である英国健康安全保障局の報告書によると、2022年にはイングランドで約58,224人が抗生物質耐性感染症に罹患し、2021年に記録された55,792例から4％増加したと推定されています。このように、薬剤耐性感染症の増加は、抗生物質耐性市場の成長を促進しています。

ヘルスケア支出の増加は、抗生物質耐性市場の成長軌道を加速させる構えです。ヘルスケア支出は、特定の期間内にヘルスケア関連の商品やサービスに投資された累積財源を示します。ヘルスケア支出の増加は、抗生物質耐性感染症がもたらす課題に対抗するための革新的な治療法の研究開発および採用を促進することで、抗生物質耐性市場を推進する極めて重要な役割を果たしています。メディケア＆メディケイド・サービスセンターが2022年3月に発表した2021～2030年国民医療費（NHE）報告書によると、2021～2030年の国民医療費の年間成長率は5.1％で、6兆8,000億米ドル近くに達すると予測されています。さらに、2021年から2030年までのメディケア支出の年間成長率は7.2%、メディケイド支出の年間成長率は5.6%と予測されており、抗生物質耐性市場の拡大に医療支出の増加が大きく寄与していることが強調されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界抗生物質耐性PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の抗生物質耐性市場：成長率分析
• 世界の抗生物質耐性市場の実績：規模と成長, 2019-2024
• 世界の抗生物質耐性市場の予測：規模と成長, 2024-2029, 2034F
• 世界抗生物質耐性総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の抗生物質耐性市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ベータラクトゥム抗生物質
• セファロスポリン
• キノロン系抗生物質
• マクロライド系抗生物質
• テトラサイクリン
• オキサゾリジノン
• その他の薬物クラス
• 世界の抗生物質耐性市場病原体別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 黄色ブドウ球菌
• ブドウ球菌性肺炎
• 淋菌
• エンテロコッカス・フェシウム
• 大腸菌
• クレブシエラ肺炎
• 赤痢菌
• クロストリジウム・ディフィシル
• 世界の抗生物質耐性市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 尿路感染症
• 腹腔内感染症
• 血流感染症
• クロストリジウム・ディフィシル感染症
• その他の病気の種類
• 世界の抗生物質耐性市場作用機序による、実績と予測, 2019-2024, 2024-2029F, 2034F
• タンパク質合成阻害剤
• 細胞壁合成阻害剤
• RNA合成阻害剤
• DNA合成阻害剤
• その他の作用機序
• 世界の抗生物質耐性市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界の抗生物質耐性市場、ベータラクタム系抗生物質の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ペニシリン
• セファロスポリン
• カルバペネム
• モノバクタム
• 世界の抗生物質耐性市場セファロスポリンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 第一世代
• 第二世代
• 第三世代
• 第4世代
• 世界の抗生物質耐性市場キノロン系抗生物質のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• フルオロキノロン
• その他のキノロン
• 世界の抗生物質耐性市場マクロライド系抗生物質の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• エリスロマイシン
• アジスロマイシン
• クラリスロマイシン
• 世界の抗生物質耐性市場、テトラサイクリンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ドキシサイクリン
• ミノサイクリン
• テトラサイクリン
• 世界の抗生物質耐性市場、オキサゾリジノンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• リネゾリド
• テジゾリド
• 世界の抗生物質耐性市場、その他の薬物クラスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 糖ペプチド
• リポペプチド
• ストレプトグラミン
• ポリミキシン

第7章 地域別・国別分析

• 世界の抗生物質耐性市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の抗生物質耐性市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 抗生物質耐性市場：競合情勢
• 抗生物質耐性市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Merck and Co. Inc.
• Bristol-Myers Squibb
• Sanofi S.A.
• Thermo Fisher Scientific Inc
• AstraZeneca
• GlaxoSmithKline Plc
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Astellas Pharma
• Daiichi Sankyo
• Chugai Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• Bio-Rad Laboratories Inc
• Eppendorf Corporation
• Takara Bio Inc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 抗生物質耐性市場2029：新たな機会を提供する国
• 抗生物質耐性市場2029：新たな機会を提供するセグメント
• 抗生物質耐性市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Antimicrobial resistance refers to the phenomenon where microorganisms, including bacteria and fungi, develop the ability to withstand the effects of medications designed to eliminate them. This resistance poses a significant challenge in the treatment of infections and, in severe cases, can lead to fatalities.

The primary classes of drugs associated with antibiotic resistance include beta-lactam antibiotics, cephalosporins, quinolone antibiotics, macrolide antibiotics, tetracyclines, oxazolidinones, and others. Beta-lactam antibiotics, characterized by a beta-lactam ring in their chemical structure, work by preventing the construction of bacterial cell walls. They achieve this by covalently binding to crucial penicillin-binding proteins (PBPs), inhibiting the growth of organisms. Pathogens affected by these drugs include Staphylococcus aureus, Staphylococcus pneumonia, Neisseria gonorrhoeae, Enterococcus faecium, Escherichia coli, Klebsiella pneumonia, Shigella, Clostridium difficile, among others. These drugs are employed in the treatment of various diseases such as urinary tract infections, intra-abdominal infections, bloodstream infections, and Clostridium difficile infections. The mechanisms of action encompass protein synthesis inhibitors, cell wall synthesis inhibitors, RNA synthesis inhibitors, DNA synthesis inhibitors, and others. These drugs are utilized by diverse end-users, including hospitals, homecare, specialty clinics, and more.

The antibiotic resistance market research report is one of a series of new reports from The Business Research Company that provides antibiotic resistance market statistics, including the antibiotic resistance industry global market size, regional shares, competitors with an antibiotic resistance market share, detailed antibiotic resistance market segments, market trends, and opportunities, and any further data you may need to thrive in the antibiotic resistance industry. This antibiotic resistance market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antibiotic resistance market size has grown strongly in recent years. It will grow from $12.21 billion in 2024 to $12.89 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to lack of new antibiotics, misuse and overuse of antimicrobials in humans, animals, and plants, highly contaminated waste effluents, low vaccination rates, lack of diagnostic tools

The antibiotic resistance market size is expected to see strong growth in the next few years. It will grow to $16.97 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to incomplete treatment courses, globalization and travel, poor infection prevention and control, self-medication, cross-species transmission, high population density. Major trends in the forecast period include technological innovations in drug delivery, global collaboration for surveillance, expanding role of artificial intelligence, surge in novel therapies.

The increasing prevalence of drug-resistant infections is expected to drive the growth of the antibiotic-resistance market in the future. Drug-resistant infections are caused by bacteria that have developed resistance, making the infections significantly harder or even impossible to treat. Antimicrobial resistance drugs aid in treating various drug-resistant infections by improving antibiotic treatment outcomes for both target and non-target pathogens, depending on the specifics of resistance mechanisms and microbiome community interactions. For example, in November 2023, a report from the UK Health Security Agency, a government body, estimated that around 58,224 individuals in England had an antibiotic-resistant infection in 2022, reflecting a 4% rise from the 55,792 cases recorded in 2021. Thus, the increasing prevalence of drug-resistant infections is driving the growth of the antibiotic-resistance market.

The escalation in healthcare expenditure is poised to fuel the growth trajectory of the antibiotic resistance market. Healthcare expenditure denotes the cumulative financial resources invested in healthcare-related goods and services within a specified timeframe. Increased healthcare spending plays a pivotal role in propelling the antibiotic resistance market by fostering heightened research, development, and adoption of innovative treatments to counter the challenges posed by antibiotic-resistant infections. Notably, as per the 2021-2030 National Health Expenditure (NHE) report released by the Centers for Medicare & Medicaid Services in March 2022, projections indicate an estimated annual growth rate of 5.1% in national health spending between 2021 and 2030, reaching nearly $6.8 trillion. Moreover, the anticipated annual growth rates of 7.2% for Medicare spending and 5.6% for Medicaid spending from 2021 to 2030 underscore the substantial contribution of growing healthcare expenditure to the expansion of the antibiotic resistance market.

The antibiotic resistance market is witnessing a prominent trend centered on product innovations. Key players within this market are dedicated to pioneering innovative products to solidify their market presence. For instance, in January 2023, Alkem Laboratories Limited, an India-based pharmaceutical firm, introduced Zidavi. This novel antibiotic, a combination of ceftazidime and avibactam, addresses multi-drug resistant (MDR) infections, ensuring accessibility, affordability, and availability for critically ill patients. Zidavi, available in sterile powdered concentrate for reconstitution, offers a distinctive solution for treating infections caused by MDR gram-negative pathogens. Its formulation in single-dose vials provides an effective alternative for treating hospital-acquired pneumonia (HAP) and severe intra-abdominal infections (IAIs) linked to meropenem and colistin resistance.

Major enterprises in the antibiotic resistance market are strategically fostering partnerships to innovate and create the next generation of antimicrobial agents alongside practical diagnostics in the fight against Antimicrobial Resistance (AMR). These strategic collaborations involve leveraging complementary strengths and resources to achieve mutual success. For example, in July 2022, Boehringer Ingelheim, a Germany-based pharmaceutical company, and Evotec SE, a German biotechnology firm, joined forces with bioMerieux, a France-based diagnostic solutions provider. This partnership resulted in the formation of Aurobac Therapeutics SAS, aiming to pioneer a novel precision medicine strategy spanning diagnosis to treatment by harnessing the collective expertise of the founding companies. Their collaborative efforts aim to develop innovative antimicrobials coupled with effective diagnostics to counter the challenge posed by Antimicrobial Resistance (AMR).

In July 2022, Innoviva Inc., a pharmaceutical company based in the United States, successfully acquired Entasis Therapeutics Holdings Inc for an undisclosed sum. This strategic acquisition is designed to enhance Innoviva Inc's product portfolio focused on addressing multidrug-resistant gram-negative bacteria, providing a competitive edge in the market. Entasis Therapeutics Holdings Inc., a US-based company, specializes in the development of innovative antibacterial solutions for the treatment of severe bacterial infections resistant to conventional drugs.

Major companies operating in the antibiotic resistance market include Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, AbbVie Inc., Novartis AG, Merck and Co. Inc., Bristol-Myers Squibb, Sanofi S.A., Thermo Fisher Scientific Inc, AstraZeneca, GlaxoSmithKline Plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Astellas Pharma, Daiichi Sankyo, Chugai Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Bio-Rad Laboratories Inc, Eppendorf Corporation, Takara Bio Inc, Wockhardt Ltd., Paratek Pharmaceuticals Inc., Basilea Pharmaceutica Ltd., Theravance Biopharma Inc., Nabriva Therapeutics Plc, Seres Therapeutics Inc, Armata Pharmaceuticals Inc.

North America was the largest region in the antibiotic resistance market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibiotic resistance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the antibiotic resistance market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antibiotic resistance market consists of sales of antibiotic drug classes such as carbapenems, glycopeptide antibiotics, penicillin, fluoroquinolones, trimethoprim-sulfamethoxazole, lincosamides, aminoglycosides, polymyxins, and nitroimidazoles. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antibiotic Resistance Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antibiotic resistance market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antibiotic resistance ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antibiotic resistance market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Beta Lactum Antibiotic; Cephalosporins; Quinolones Antibiotics; Macrolide Antibiotics; Tetracyclines; Oxazolidinones; Other Drug Classes
• 2) By Pathogen: Staphylococcus Aureus; Staphylococcus Pneumonia; Neisseria Gonorrhoeae; Enterococcus Faecium; Escherichia Coli; Klebsiella Pneumonia; Shigella; Clostridium Difficile; Other Pathogens
• 3) By Disease Type: Urinary Tract Infection; Intra-Abdominal Infection; Blood Stream infections; Clostridium Difficile Infections; Other Disease Types
• 4) By Mechanism Of Action: Protein Synthesis Inhibitors; Cell Wall Synthesis Inhibitors; RNA Synthesis Inhibitors; DNA Synthesis Inhibitors; Other Mechanism Of Actions
• 5) By End Users: Hospitals; Homecare; Specialty Clinics; Other End-users
• Subsegments:
• 1) By Beta Lactam Antibiotics: Penicillins; Cephalosporins; Carbapenems; Monobactams
• 2) By Cephalosporins: First-generation; Second-generation; Third-generation; Fourth-generation
• 3) By Quinolones Antibiotics: Fluoroquinolones; Other Quinolones
• 4) By Macrolide Antibiotics: Erythromycin; Azithromycin; Clarithromycin
• 5) By Tetracyclines: Doxycycline; Minocycline; Tetracycline
• 6) By Oxazolidinones: Linezolid; Tedizolid
• 7) By Other Drug Classes: Glycopeptides; Lipopeptides; Streptogramins; Polymyxins
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson; F. Hoffmann-La Roche Ltd; AbbVie Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Antibiotic Resistance Market Characteristics

3. Antibiotic Resistance Market Trends And Strategies

4. Antibiotic Resistance Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Antibiotic Resistance Growth Analysis And Strategic Analysis Framework

• 5.1. Global Antibiotic Resistance PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Antibiotic Resistance Market Growth Rate Analysis
• 5.4. Global Antibiotic Resistance Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Antibiotic Resistance Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Antibiotic Resistance Total Addressable Market (TAM)

6. Antibiotic Resistance Market Segmentation

• 6.1. Global Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Beta Lactum Antibiotic
• Cephalosporins
• Quinolones Antibiotics
• Macrolide Antibiotics
• Tetracyclines
• Oxazolidinones
• Other Drug Classes
• 6.2. Global Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Staphylococcus Aureus
• Staphylococcus Pneumonia
• Neisseria Gonorrhoeae
• Enterococcus Faecium
• Escherichia Coli
• Klebsiella Pneumonia
• Shigella
• Clostridium Difficile
• 6.3. Global Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Urinary Tract Infection
• Intra-Abdominal Infection
• Blood Stream infections
• Clostridium Difficile Infections
• Other Disease Types
• 6.4. Global Antibiotic Resistance Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Protein Synthesis Inhibitors
• Cell Wall Synthesis Inhibitors
• RNA Synthesis Inhibitors
• DNA Synthesis Inhibitors
• Other Mechanism Of Actions
• 6.5. Global Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End-users
• 6.6. Global Antibiotic Resistance Market, Sub-Segmentation Of Beta Lactam Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Penicillins
• Cephalosporins
• Carbapenems
• Monobactams
• 6.7. Global Antibiotic Resistance Market, Sub-Segmentation Of Cephalosporins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• First-generation
• Second-generation
• Third-generation
• Fourth-generation
• 6.8. Global Antibiotic Resistance Market, Sub-Segmentation Of Quinolones Antibiotics,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fluoroquinolones
• Other Quinolones
• 6.9. Global Antibiotic Resistance Market, Sub-Segmentation Of Macrolide Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Erythromycin
• Azithromycin
• Clarithromycin
• 6.10. Global Antibiotic Resistance Market, Sub-Segmentation Of Tetracyclines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Doxycycline
• Minocycline
• Tetracycline
• 6.11. Global Antibiotic Resistance Market, Sub-Segmentation Of Oxazolidinones, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Linezolid
• Tedizolid
• 6.12. Global Antibiotic Resistance Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Glycopeptides
• Lipopeptides
• Streptogramins
• Polymyxins

7. Antibiotic Resistance Market Regional And Country Analysis

• 7.1. Global Antibiotic Resistance Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Antibiotic Resistance Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Antibiotic Resistance Market

• 8.1. Asia-Pacific Antibiotic Resistance Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Antibiotic Resistance Market

• 9.1. China Antibiotic Resistance Market Overview
• 9.2. China Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Antibiotic Resistance Market

• 10.1. India Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Antibiotic Resistance Market

• 11.1. Japan Antibiotic Resistance Market Overview
• 11.2. Japan Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Antibiotic Resistance Market

• 12.1. Australia Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Antibiotic Resistance Market

• 13.1. Indonesia Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Antibiotic Resistance Market

• 14.1. South Korea Antibiotic Resistance Market Overview
• 14.2. South Korea Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Antibiotic Resistance Market

• 15.1. Western Europe Antibiotic Resistance Market Overview
• 15.2. Western Europe Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Antibiotic Resistance Market

• 16.1. UK Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Antibiotic Resistance Market

• 17.1. Germany Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Antibiotic Resistance Market

• 18.1. France Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Antibiotic Resistance Market

• 19.1. Italy Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Antibiotic Resistance Market

• 20.1. Spain Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Antibiotic Resistance Market

• 21.1. Eastern Europe Antibiotic Resistance Market Overview
• 21.2. Eastern Europe Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Antibiotic Resistance Market

• 22.1. Russia Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Antibiotic Resistance Market

• 23.1. North America Antibiotic Resistance Market Overview
• 23.2. North America Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Antibiotic Resistance Market

• 24.1. USA Antibiotic Resistance Market Overview
• 24.2. USA Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Antibiotic Resistance Market

• 25.1. Canada Antibiotic Resistance Market Overview
• 25.2. Canada Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Antibiotic Resistance Market

• 26.1. South America Antibiotic Resistance Market Overview
• 26.2. South America Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Antibiotic Resistance Market

• 27.1. Brazil Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Antibiotic Resistance Market

• 28.1. Middle East Antibiotic Resistance Market Overview
• 28.2. Middle East Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Antibiotic Resistance Market

• 29.1. Africa Antibiotic Resistance Market Overview
• 29.2. Africa Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Antibiotic Resistance Market Competitive Landscape And Company Profiles

• 30.1. Antibiotic Resistance Market Competitive Landscape
• 30.2. Antibiotic Resistance Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Antibiotic Resistance Market Other Major And Innovative Companies

• 31.1. Merck and Co. Inc.
• 31.2. Bristol-Myers Squibb
• 31.3. Sanofi S.A.
• 31.4. Thermo Fisher Scientific Inc
• 31.5. AstraZeneca
• 31.6. GlaxoSmithKline Plc
• 31.7. Eli Lilly and Company
• 31.8. Boehringer Ingelheim International GmbH
• 31.9. Astellas Pharma
• 31.10. Daiichi Sankyo
• 31.11. Chugai Pharmaceutical Co. Ltd.
• 31.12. Teva Pharmaceutical Industries Ltd.
• 31.13. Bio-Rad Laboratories Inc
• 31.14. Eppendorf Corporation
• 31.15. Takara Bio Inc

32. Global Antibiotic Resistance Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Antibiotic Resistance Market

34. Recent Developments In The Antibiotic Resistance Market

35. Antibiotic Resistance Market High Potential Countries, Segments and Strategies

• 35.1 Antibiotic Resistance Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Antibiotic Resistance Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Antibiotic Resistance Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer